Huyen Thi Lam Nguyen

Huyen Thi Lam Nguyen

Auto-generated profile, based on publicly available information

Huyen Thi Lam Nguyen

Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Science Advances
Verified
Journal Article
Open access
ASAhmad Al Shihabi
Ahmad Al Shihabi
ADArdalan Davarifar
Ardalan Davarifar
HNHuyen Thi Lam Nguyen
Huyen Thi Lam Nguyen
NTNasrin Tavanaie
Nasrin Tavanaie
SNScott D. Nelson
Scott D. Nelson
ASAlice Soragni
Alice Soragni
Chordomas are rare tumors of notochordal origin, most commonly arising in the sacrum or skull base. Chordomas are considered insensitive to conventional chemotherapy, and their rarity complicates running timely and adequately powered trials to identify effective treatments. Therefore, there is a need for discovery of novel therapeutic approaches. Patient-derived organoids can accelerate drug discovery and development studies and predict patient responses to therapy. In this proof-of-concept study, we successfully established organoids from seven chordoma tumor samples obtained from five patients presenting with tumors in different sites and stages of disease. The organoids recapitulated features of the original parent tumors and inter- as well as intrapatient heterogeneity. High-throughput screenings performed on the organoids highlighted targeted agents such as PI3K/mTOR, EGFR, and JAK2/STAT3 inhibitors among the most effective molecules. Pathway analysis underscored how the NF-κB and IGF-1R pathways are sensitive to perturbations and potential targets to pursue for combination therapy of chordoma.